The estimated Net Worth of Robert Michael Ii Savel is at least 843 千$ dollars as of 25 March 2022. Mr. Savel owns over 5,699 units of Otonomy Inc stock worth over 11,222$ and over the last 18 years he sold OTIC stock worth over 13,678$. In addition, he makes 817,760$ as Chief Technical Officer at Otonomy Inc.
Sign up
Mr. Savel OTIC stock SEC Form 4 insiders trading
Robert has made over 5 trades of the Otonomy Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 5,699 units of OTIC stock worth 13,678$ on 25 March 2022.
The largest trade he's ever made was exercising 25,000 units of Otonomy Inc stock on 15 June 2015 worth over 111,500$. On average, Robert trades about 2,539 units every 138 days since 2007. As of 25 March 2022 he still owns at least 145,735 units of Otonomy Inc stock.
You can see the complete history of Mr. Savel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert Savel biography
Robert Michael Savel, II serves as Chief Technical Officer of the Company. From September 2011 to December 2013, Mr. Savel served as General Manager and Senior Vice President of Operations for Optimer Pharmaceuticals, Inc., a biopharmaceutical company. From September 2010 to June 2011, Mr. Savel served as Senior Vice President and Chief Technical Officer for Inspire Pharmaceuticals, Inc., an ophthalmic pharmaceutical company. From April 2008 to September 2010, Mr. Savel served as President of Savel Enterprises LLC, a management consulting firm. From April 2007 to April 2008, Mr. Savel served as the Senior Vice President of Technical Operations for PDL BioPharma, a biotech company. Earlier in his career, he held leadership operating positions with Johnson & Johnson, a medical device, pharmaceutical and consumer packaged goods manufacturer, which included the position of Vice President, Quality and Compliance. Mr. Savel received his Bachelor’s degree in mechanical engineering from Virginia Polytechnic Institute and State University in Blacksburg, Virginia.
What is the salary of Robert Savel?
As the Chief Technical Officer of Otonomy Inc, the total compensation of Robert Savel at Otonomy Inc is 817,760$. There are 3 executives at Otonomy Inc getting paid more, with David Weber having the highest compensation of 2,153,120$.
How old is Robert Savel?
Robert Savel is 52, he's been the Chief Technical Officer of Otonomy Inc since 2014. There are 11 older and 2 younger executives at Otonomy Inc. The oldest executive at Otonomy Inc is James Breitmeyer, 66, who is the Independent Director.
What's Robert Savel's mailing address?
Robert's mailing address filed with the SEC is C/O OTONOMY, INC., 4796 EXECUTIVE DRIVE, SAN DIEGO, CA, 92121.
Insiders trading at Otonomy Inc
Over the last 10 years, insiders at Otonomy Inc have traded over 30,282,796$ worth of Otonomy Inc stock and bought 755,065 units worth 12,114,945$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Holdings A/S Novo、Brian H Dovey. On average, Otonomy Inc executives and independent directors trade stock every 66 days with the average trade being worth of 7,317$. The most recent stock trade was executed by Vickie L Capps on 28 November 2022, trading 42,242 units of OTIC stock currently worth 4,224$.
What does Otonomy Inc do?
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière's disease, hearing loss, and tinnitus.
What does Otonomy Inc's logo look like?
Complete history of Mr. Savel stock trades at Otonomy Inc、PDL Biopharma Inc
Otonomy Inc executives and stock owners
Otonomy Inc executives and other stock owners filed with the SEC include:
-
David Weber,
President, Chief Executive Officer, Director -
Dr. David Allen Weber,
Pres, CEO & Director -
Paul Cayer,
Chief Financial and Business Officer -
Robert Savel,
Chief Technical Officer -
Paul E. Cayer,
Chief Financial & Bus. Officer -
Robert Michael Savel II,
Chief Technical Officer -
Jay Lichter,
Independent Chairman of the Board -
Vickie Capps,
Independent Director -
Iain McGill,
Independent Director -
James Breitmeyer,
Independent Director -
Theodore Schroeder,
Independent Director -
Dr. Jay B. Lichter Ph.D.,
Co-Founder & Independent Chairman -
Ciara Kennedy,
Independent Director -
James Branch CPA,
VP of Fin. & Controller -
David Skarinsky,
Sr. VP of Clinical -
Breianna Bowen,
VP of HR -
Fabrice Piu Ph.D.,
Sr. VP of Preclinical Devel. -
Barbara M. Finn,
Sr. VP of Regulatory Affairs & Quality Assurance -
Dr. Alan Charles Foster Ph.D.,
Chief Scientific Officer -
Julie D. Burgess,
VP of Fin. & Admin. -
Dr. Rick Adam Friedman M.D., Ph.D.,
Co-Founder and Member of the Advisory Panel -
Dr. Allen F. Ryan Ph.D.,
Co-Founder and Member of the Advisory Panel -
Katherine Mary Bishop,
Chief Scientific Officer -
Eric J Loumeau,
GC & Chief Compliance Officer -
Carl Le Bel,
Chief Scientific Officer -
Heather Preston,
Director -
George J Morrow,
Director -
Advisors Llc Orbi Med Capit...,
-
Chau Quang Khuong,
Director -
Anthony J Yost,
Chief Commercial Officer -
Dean Hakanson,
Chief Medical Officer -
John P Mckearn,
Director -
Partners Viii, L.P.Blair Ja...,
-
Ventures Viii Lp Avalon Ven...,
-
Holdings A/S Novo,
10% owner -
Group Holdings (Sbs) Adviso...,
-
Viii Associates, L.P.Domain...,
-
Alan Charles Foster,
Chief Scientific Officer -
Brian H Dovey,
Director -
Jill Marie Broadfoot,
Director